To access this material please log in or register

Register Authorize

Current biomarkers of kidney injury: Clinical and prognostic significance

Ponomarenko I. V.1, Sukmanova I. A.2
1 – Territorial State Budgetary Institution of Health Care “Altai regional cardiological dispensary”, Malakhov street 46, Barnaul, Altai Territory 656055
2 – Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation, Prospekt Lenina 40, Barnaul, Altai Territory 656038

Keywords: acute kidney injury, biomarkers, diagnostics, prognosis

DOI: 10.18087/rhj.2017.3.2359

It is presently proved that impaired kidney function is associated with a high risk of cardiovascular diseases. During the recent decade, the incidence of acute kidney injury (AKI) has been continuously growing due to more frequent use of interventional methods of examination and treatment. AKI increases the risk for development of complications, duration of stay in a hospital, and in-hospital mortality. This disease is generally diagnosed retrospectively, when increased creatinine and decreased GFR are observed, which may occur in several days after the onset and completion of the effect of a damaging factor. Early diagnosis and timely administration of therapy are the major tasks in AKI. Therefore, searching for current biomarkers of kidney injury is a relevant issue. This review presents up-to-date information on known and novel, promising substances, which can be used as biomarkers for functional and structural kidney injury.
  1. Miyasaka Y. Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence. Circulation. 2006;114(2):119–25. DOI:10.1161/CIRCULATIONAHA.105.595140.
  2. Сулимов В. А., Голицын С. П., Панченко Е. П., Попов С. В., Ревишвили А. Ш., Шубик Ю. В. и др. Диагностика и лечение фибрилляций предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал. 2013;4 S3:-1–100 [Sulimov V. A., Goliczy`n S. P., Panchenko E. P., Popov S. V., Revishvili A. Sh., Shubik Yu. V. i dr. Diagnostika i lechenie fibrillyaczij predserdij. Rekomendaczii RKO, VNOA i ASSX. Rossijskij kardiologicheskij zhurnal. 2013;4 S3:1–100].
  3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. DOI:10.1093/eurheartj/ehw210.
  4. Бритов А. Н., Поздняков Ю. М., Волкова Э. Г., Драпкина О. М., Еганян Р. А., Кисляк О. М. и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6 S2):1–64 [Britov A. N., Pozdnyakov Yu. M., Volkova E`. G., Drapkina O. M., Eganyan R. A., Kislyak O. M. i dr. Naczional`ny`e rekomendaczii po kardiovaskulyarnoj profilaktike. Kardiovaskulyarnaya terapiya i profilaktika. 2011;10(6 S2):1–64].
  5. Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P et al. Recommendations for chamber quantification. European Journal of Echocardiography. 2006;7(2):79–108. DOI:10.1016/j.euje.2005.12.014.
  6. Шафранская К. С., Кашталап В. В., Баздырев Е. Д., Барбараш О. Л. Возможности диагностики острого повреждения почек с использованием липокалина, ассоциированного с желатиназой нейтрофилов (NGAL) в кардиологии (обзор литературы). Сибирский медицинский журнал (г. Томск). 2011;26-(4–1):15–9 [Shafranskaya K. S., Kashtalap V. V., Bazdy`rev E. D., Barbarash O. L. Vozmozhnosti diagnostiki ostrogo povrezhdeniya pochek s ispol`zovaniem lipokalina, assocziirovannogo s zhelatinazoj nejtrofilov (NGAL) v kardiologii (obzor literatury`). Sibirskij mediczinskij zhurnal (g. Tomsk). 2011;26(4–1):15–9].
  7. Алексеев А. В., Гильманов А. Ж., Гатиятуллина Р. С., Ракипов И. Г. Современные биомаркеры острого повреждения почек. Практическая медицина. 2014;3:22–7 [Alekseev A. V., Gil`manov A. Zh., Gatiyatullina R . S., Rakipov I. G. Sovremenny`e biomarkery` ostrogo povrezhdeniya pochek. Prakticheskaya mediczina. 2014;3:22–7].
  8. de Geus HRH, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clinical Kidney Journal. 2012;5(2):102–8. DOI:10.1093/ckj/sfs008.
  9. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. European Heart Journal. 2016;37(20):1591–602. DOI:10.1093/eurheartj/ehw007.
  10. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. International Journal of Cardiology. 2014;170(3):303–8. DOI:10.1016/j.ijcard.2013.11.002.
  11. Boyd AC, McKay T, Nasibi S, Richards DAB, Thomas L. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. European Heart Journal - Cardiovascular Imaging. 2013;14(3):269–75. DOI:10.1093/ehjcijes153.
  12. Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S et al. Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). The American Journal of Cardiology. 2014;113(4):669–75. DOI:10.1016/j.amjcard.2013.10.045.
  13. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis. Circulation. 2007;115(4):459–67. DOI:10.1161/CIRCULATIONAHA.106.628875.
  14. Bekwelem W, Jensen PN, Norby FL, Soliman EZ, Agarwal SK, Lip GYH et al. Carotid Atherosclerosis and Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Stroke. 2016;47(6):1643–6. DOI:10.1161/STROKEAHA.116.013133.
  15. Devarajan P. Neutrophil gelatinase associated lipocalin (NGAL): A new marker of kidney disease. Scandinavian Journal of Clinical and Laboratory Investigation. 2008;68(sup241):89–94. DOI:10.1080/00365510802150158.
  16. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4(2):265–80. DOI:10.2217/bmm.10.12.
  17. Liu X, Wang Z, Yang Q, Yu M, Shen H, Nie B et al. Plasma neutrophil-gelatinase-associated lipocalin and cystatin C could early diagnose contrast-induced acute kidney injury in patients with renal insufficiency undergoing an elective percutaneous coronary intervention. Chin Med J. 2012;125(6):1051–6.
  18. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clinical Chemistry and Laboratory Medicine (CCLM). 2012;50(9):1505–17. DOI:10.1515/cclm-2011-0814.
  19. Woo K-S, Choi J-L, Kim B-R, Kim J-E, An W-S, Han J-Y. Urinary Neutrophil Gelatinase-Associated Lipocalin Levels in Comparison with Glomerular Filtration Rate for Evaluation of Renal Function in Patients with Diabetic Chronic Kidney Disease. Diabetes & Metabolism Journal. 2012;36(4):307. DOI:10.4093/dmj.2012.36.4.307.
  20. Blumczynski A, Sołtysiak J, Lipkowska K, Silska M, Poprawska A, Musielak A et al. Hypertensive nephropathy in children – do we diagnose early enough? Blood Pressure. 2012;21(4):233–9. DOI:10.3109/08037051.2012.666393.
  21. Hollmen ME, Kyllönen LE, Inkinen KA, Lalla MLT, Salmela KT. Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney International. 2011;79(1):89–98. DOI:10.1038/ki.2010.351.
  22. Devarajan P. Biomarkers for the early detection of acute kidney injury: Current Opinion in Pediatrics. 2011;23(2):194–200. DOI:10.1097/MOP.0b013e328343f4dd.
  23. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135–42.
  24. Vaidya VS. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. AJP: Renal Physiology. 2006;290(2):F517–29. DOI:10.1152/ajprenal.00291.2005.
  25. Vaidya VS, Ford GM, Waikar SS, Wang Y, Clement MB, Ramirez V et al. A rapid urine test for early detection of kidney injury. Kidney International. 2009;76(1):108–14. DOI:10.1038/ki.2009.96.
  26. Han WK, Bailly V, Abichandani R , Thadhani R , Bonventre JV. Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney International. 2002;62(1):237–44. DOI:10.1046/j.1523-1755.2002.00433.x.
  27. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H et al. Urinary N-Acetyl-beta-(D)-Glucosaminidase Activity and Kidney Injury Molecule-1 Level Are Associated with Adverse Outcomes in Acute Renal Failure. Journal of the American Society of Nephrology. 2007;18(3):904–12. DOI:10.1681/ASN.2006030221.
  28. Szeto C-C, Kwan BC-H, Lai K-B, Lai FM-M, Chow K-M, Wang G et al. Urinary Expression of Kidney Injury Markers in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology. 2010;5(12):2329–37. DOI:10.2215/CJN.01910310.
  29. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I et al. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial. American Journal of Kidney Diseases. 2009;53(1):16–25. DOI:10.1053/j.ajkd.2008.07.021.
  30. Jungbauer CG, Birner C, Jung B, Buchner S, Lubnow M, von Bary C et al. Kidney injury molecule-1 and N-acetyl-ß-d-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. European Journal of Heart Failure. 2011;13(10):1104–10. DOI:10.1093/eurjhf/hfr102.
  31. Горда И. И., Безродный А. Б., Василенко О. В., Данькевич И. В. Маркеры острого повреждения почек. Сердце и сосуды. 2012;3:108–13 [Gorda I. I., Bezrodny`j A. B., Vasilenko O. V., Dan`kevich I. V. Markery` ostrogo povrezhdeniya pochek. Serdcze i sosudy`. 2012;3:108–13].
  32. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. American Journal of Kidney Diseases. 2004;43(3):405–14. DOI:10.1053/j.ajkd.2003.10.040.
  33. Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney International. 2006;70(1):199–203. DOI:10.1038/sj.ki.5001527.
  34. Waikar SS. Declining Mortality in Patients with Acute Renal Failure, 1988 to 2002. Journal of the American Society of Nephrology. 2006;17(4):1143–50. DOI:10.1681/ASN.2005091017.
  35. He Z, Lu L, Altmann C, Hoke TS, Ljubanovic D, Jani A et al. Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. Am J Physiol Renal Physiol. 2008;295(5):F1414-1421. DOI:10.1152/ajprenal.90288.2008.
  36. Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL. Neutrophil-independent mechanisms of cas-pase-1– and IL-18–mediated ischemic acute tubular necrosis in mice. Journal of Clinical Investigation. 2002;110(8):1083–91. DOI:10.1172/JCI15623.
  37. Wu H, Craft ML, Wang P, Wyburn KR, Chen G, Ma J et al. IL-18 Contributes to Renal Damage after Ischemia-Reperfusion. Journal of the American Society of Nephrology. 2008;19(12):2331–41. DOI:10.1681/ASN.2008020170.
  38. Kamijo-Ikemori A, Ichikawa D, Matsui K, Yokoyama T, Sugaya T, Kimura K. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan]. Rinsho Byori. 2013;61(7):635–40.
  39. Liu X, Guan Y, Xu S, Li Q, Sun Y, Han R et al. Early Predictors of Acute Kidney Injury: A Narrative Review. Kidney and Blood Pressure Research. 2016;41(5):680–700. DOI:10.1159/000447937.
  40. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney International. 2008;73(7):863–9. DOI:10.1038/sj.ki.5002715.
  41. Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotechnology. 2010;28(5):486–94. DOI:10.1038/nbt.1627.
  42. Harpur E, Ennulat D, Hoffman D, Betton G, Gautier J-C, Riefke B et al. Biological Qualification of Biomarkers of Chemical-Induced Renal Toxicity in Two Strains of Male Rat. Toxicological Sciences. 2011;122(2):235–52. DOI:10.1093/toxsci/kfr112.
  43. Ishii A, Sakai Y, Nakamura A. Molecular Pathological Evaluation of Clusterin in a Rat Model of Unilateral Ureteral Obstruction as a Possible Biomarker of Nephrotoxicity. Toxicologic Pathology. 2007;35(3):376–82. DOI:10.1080/01926230701230320.
  44. Kaskow BJ, Michael Proffit J, Blangero J, Moses EK, Abraham LJ. Diverse biological activities of the vascular non-inflammatory molecules – The Vanin pantetheinases. Biochemical and Biophysical Research Communications. 2012;417(2):653–8. DOI:10.1016/j.bbrc.2011.11.099.
  45. Hosohata K, Ando H, Fujimura A. Early detection of renal injury using urinary vanin-1 in rats with experimental colitis: Vanin-1 as a biomarker for renal injury in colitis. Journal of Applied Toxicology. 2014;34(2):184–90. DOI:10.1002/jat.2849.
  46. Lu Y, He R, Xu Q, Peng B, Li J. [Comparative study on external use of mercury-containing preparation badu shengji san in sensitive monitoring indicators of induced early renal injury]. Zhongguo Zhong Yao Za Zhi. 2012;37(6):706–10.
  47. Barrera-Chimal J, Pérez-Villalva R, Cortés-González C, Ojeda-Cervantes M, Gamba G, Morales-Buenrostro LE et al. Hsp72 is an early and sensitive biomarker to detect acute kidney injury: Hsp72 as a novel biomarker to detect AKI. EMBO Molecular Medicine. 2011;3(1):5–20. DOI:10.1002/emmm.201000105.
  48. Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clinical Toxicology. 2011;49(8):720–8. DOI:10.3109/15563650.2011.615319.
  49. Haase M, Bellomo R, Devarajan P, Ma Q, Bennett MR, Möckel M et al. Novel Biomarkers Early Predict the Severity of Acute Kidney Injury After Cardiac Surgery in Adults. The Annals of Thoracic Surgery. 2009;88(1):124–30. DOI:10.1016/j.athoracsur.2009.04.023.
Ponomarenko I. V., Sukmanova I. A. Current biomarkers of kidney injury: Clinical and prognostic significance. Russian Heart Journal. 2017;16 (3):168–176

To access this material please log in or register

Register Authorize
Ru En